For Q1 FY2026 (ended March 31, 2026), Evommune reported no revenue, compared to revenue in the prior year period. Net loss was $21.7 million, widening 48.9% year-over-year, with operating loss of $24.0 million (up 59.4%). Diluted EPS was -$0.64, compared to -$0.33 in Q1 FY2025. The company held $48.3 million in cash and $304.6 million in equity as of quarter-end.
•Revenue was $0, down 100% year-over-year.
•Net loss of $21.7 million, 48.9% wider than Q1 FY2025.
•Operating loss of $24.0 million, up 59.4%.
•Cash and cash equivalents of $48.3 million; equity of $304.6 million.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Evommune is a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.
Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
Evommune, Inc. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory diseases. Its initial clinical programs target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The company's lead product candidate, EVO756, is being developed for the treatment of CSU and AD. Another candidate, EVO301, targets AD and UC. Evommune aims to address key drivers of inflammation in these conditions, offering potential new treatment options for patients.
On which stock exchange is Evommune (EVMN) listed and in what currency?
Evommune, Inc. is listed on the New York Stock Exchange (NYSE) under the ticker symbol EVMN. The company's stock trades in US Dollars (USD), reflecting its primary listing in the United States. As a US-based company, its financial reporting and market transactions are conducted in USD.
What sector and industry does Evommune (EVMN) operate in?
Evommune operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing innovative therapies for diseases, particularly chronic inflammatory conditions. The company's work involves advanced biological and molecular approaches to create treatments that target specific disease pathways.
Where is Evommune headquartered and what is its background?
Evommune, Inc. is headquartered in Palo Alto, California, United States. The company was incorporated in 2020, making it a relatively young player in the biotechnology field. Its location in Palo Alto places it within a major hub for biotechnology and innovation, providing access to talent, research collaborations, and the broader life sciences ecosystem.
What are Evommune's main product candidates and their target indications?
Evommune's pipeline includes two main product candidates. EVO756 is being developed for chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), both chronic inflammatory skin conditions. EVO301 targets atopic dermatitis (AD) and ulcerative colitis (UC), an inflammatory bowel disease. These candidates are in clinical-stage development, meaning they are being tested in human trials to evaluate safety and efficacy. The company's focus on these indications addresses significant unmet medical needs in inflammatory diseases.